Roche Launches Tecentriq SC in India, Bringing 7-Minute Immunotherapy to Lung Cancer Care

Roche Pharma India has announced the launch of Tecentriq SC, or subcutaneous atezolizumab, marking an important development in India’s lung cancer treatment landscape. The medicine is being positioned as India’s first under-the-skin immunotherapy for lung cancer, with administration taking approximately 7 minutes, compared with conventional intravenous immunotherapy infusions that may take several hours.

The launch is significant because cancer treatment is not only about the medicine itself; it is also about the time, travel, hospital infrastructure and emotional burden involved in repeated therapy cycles. For many patients, especially those travelling from smaller towns to large cancer centres, long infusion schedules can mean full-day hospital visits, caregiver disruption and additional indirect costs. A faster subcutaneous formulation can reduce treatment chair time, ease pressure on oncology day-care units and make treatment delivery more practical for hospitals and patients.

Tecentriq, whose generic name is atezolizumab, is a cancer immunotherapy. Roche India describes it as a monoclonal antibody designed to target PD-L1 proteins found on tumour cells and tumour-infiltrating immune cells. By blocking the PD-L1 pathway, the drug is intended to help the immune system recognise and attack cancer cells more effectively. Roche India lists approved indications for Tecentriq including metastatic non-small cell lung cancer, extensive-stage small cell lung cancer, triple-negative breast cancer, hepatocellular carcinoma and metastatic urothelial carcinoma.

In India, the new subcutaneous version has been approved by the Drugs Controller General of India for adjuvant and metastatic non-small cell lung cancer, according to the BioSpectrum report. The CDSCO Technical Committee records also show that Roche Products India had sought approval to import and market Atezolizumab injection 1875 mg/15 mL vial for subcutaneous administration for NSCLC indications, with a Phase IV trial commitment in India. The committee recommended approval with the condition that Roche conduct a Phase IV clinical trial in India covering the applied NSCLC indications.

Globally, Tecentriq SC has already moved through major regulatory systems. BioSpectrum reports that it was first approved by the UK’s MHRA in 2023 and later by the US FDA in 2024, and is now approved in more than 85 countries, with more than 10,000 patients having benefited globally. Roche’s own global release notes that the subcutaneous version combines Tecentriq with Halozyme’s Enhanze drug-delivery technology, which uses recombinant human hyaluronidase PH20 to temporarily increase permeability under the skin, allowing the medicine to disperse and absorb more rapidly.

The clinical basis for the subcutaneous formulation comes from the IMscin001 study, a global Phase Ib/III trial comparing Tecentriq SC with Tecentriq IV in patients with previously treated locally advanced or metastatic NSCLC. Roche reported that the study demonstrated comparable drug levels in the blood during the dosing interval, while efficacy measures such as overall response rate and progression-free survival were similar between the subcutaneous and intravenous arms and consistent with the known profile of IV Tecentriq. The safety profile of Tecentriq SC was also reported as consistent with IV Tecentriq.

The Indian launch comes at a time when lung cancer remains one of the most serious oncology challenges in the country. Mint, citing company statements, reported that India sees around 80,000 lung cancer cases annually, with a large share diagnosed at advanced stages. ET Pharma also reported that patients require biomarker testing to determine eligibility and that Roche estimates nearly half of India’s lung cancer patients may be eligible for Tecentriq.

However, this should be understood carefully. Tecentriq SC is not a general cancer injection, not a preventive medicine and not something patients can choose casually. It is a specialised immunotherapy for selected patients, based on cancer type, disease stage, biomarkers, previous treatment history and oncologist assessment. The medicine must be prescribed and administered under specialist medical supervision, and patients should rely on their treating oncologist for decisions on eligibility, dosing, side effects and treatment duration.

The larger importance of Tecentriq SC lies in how it may reshape cancer-care logistics. India’s tertiary cancer hospitals are often crowded, and infusion-chair capacity is a real bottleneck. A treatment that can be given in minutes instead of hours may help oncology teams manage more patients efficiently, reduce waiting time and improve the overall care experience. For patients, that could mean less time in hospital corridors and more time at home between treatment cycles.

Roche’s India launch therefore represents more than the arrival of another branded oncology drug. It reflects a broader shift in modern cancer care: therapies are being redesigned not only for clinical outcomes but also for patient convenience, hospital efficiency and real-world access. In a country where cancer treatment often requires long travel, repeated hospital visits and major family support, a 7-minute immunotherapy option could become a meaningful step toward more patient-friendly oncology.